The DOI matches its Crossref record; 20 of the 22 references it cites were found in a registry or an index.
Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial
Abstract
Background A subcutaneous formulation of trastuzumab has been developed, offering potential improvements in patient convenience and resource use compared with the standard intravenous infusion of the drug. We compared the pharmacokinetic profile, efficacy, and safety of the subcutaneous and intravenous formulations in patients with HER2-positive early breast cancer.Methods The HannaH study was a phase 3, randomised, international, open-label, trial in the (neo)adjuvant setting. Patients with HER2-positive, operable, locally advanced or inflammatory breast cancer were randomly assigned to eight cycles of neoadjuvant chemotherapy administered concurrently with trastuzumab every 3 weeks either intravenously (8 mg/kg loading dose, 6 mg/kg maintenance dose) or subcutaneously (fixed dose of 600 mg); 1:1 ratio. Chemotherapy consisted of four cycles of docetaxel (75 mg/m(2)) followed by four cycles of fluorouracil (500 mg/m(2)), epirubicin (75 mg/m(2)), and cyclophosphamide (500 mg/m(2)), every 3 weeks. After surgery, patients continued trastuzumab to complete 1 year of treatment. Coprimary endpoints were serum trough concentration (C(trough)) at pre-dose cycle 8 before surgery (non-inferiority margin for the ratio between groups of 0·80) and pathological complete response (pCR; non-inferiority margin for the difference between groups of -12·5%), analysed in the per-protocol population. This study is registered with ClinicalTrials.gov, number NCT00950300.Findings 299 patients were randomly assigned to receive intravenous trastuzumab and 297 to receive subcutaneous trastuzumab. The geometric mean presurgery C(trough) was 51·8 μg/mL (coefficient of variation 52·5%) in the intravenous group and 69·0 μg/mL (55·8%) in the subcutaneous group. The geometric mean ratio of C(trough) subcutaneous to C(trough) intravenous was 1·33 (90% CI 1·24-1·44). 107 (40·7%) of 263 patients in the intravenous group and 118 (45·4%) of 260 in the subcutaneous group achieved a pCR. The difference between groups in pCR was 4·7% (95% CI -4·0 to 13·4). Thus subcutaneous trastuzumab was non-inferior to intravenous trastuzumab for both coprimary endpoints. The incidence of grade 3-5 adverse events was similar between groups. The most common of these adverse events were neutropenia (99 [33·2%] of 298 patients in the intravenous group vs 86 [29·0%] of 297 in the subcutaneous group), leucopenia (17 [5·7%] vs 12 [4·0%]), and febrile neutropenia (10 [3·4%] vs 17 [5·7%]). However, more patients had serious adverse events in the subcutaneous group (62 [21%] of 297 patients) than in the intravenous group (37 [12%] of 298); the difference was mainly attributable to infections and infestations (24 [8·1%] in the subcutaneous group vs 13 [4·4%] in the intravenous group). Four adverse events led to death (one in the intravenous group and three in the subcutaneous group), all of which occurred during the neoadjuvant phase. Of these, two--both in the subcutaneous group--were deemed to be treatment related.Interpretation Subcutaneous trastuzumab, administered over about 5 min, has a pharmacokinetic profile and efficacy non-inferior to standard intravenous administration, with a similar safety profile to intravenous trastuzumab, and therefore offers a valid treatment alternative.Funding F Hoffmann-La Roche.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“SC trastuzumab was shown to be non-inferior to IV, for both co-primary endpoints (serum trough concentration at pre-dose cycle 8 and pathologic complete response rates), demonstrating that the SC formulation is a valid treatment alternative to IV [31–34].”
From A systematic review of time and resource use costs of subcutaneous versus intravenous administration of oncology biologics in a hospital setting (2023) · cites this paper as [31]
In the citing paper
“In HannaH, the geometric mean ratio of Ctrough subcutaneous to Ctrough intravenous was 1.33 (90% CI 1.24–1.44)”
From Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities (2018) · cites this paper as [39]
In the citing paper
“In both the HannaH and the Sabrina studies, subcutaneous administration of trastuzumab and rituximab resulted in noninferior Ctrough and efficacy to intravenous dosing and a similar safety profile [21, 39, 74].”
From Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities (2018) · cites this paper as [39]
In the citing paper
“When developing the subcutaneous formulation for trastuzumab and rituximab, the change from intravenous to subcutaneous administration included a switch from weight- and body surface area-adjusted dosing to a fixed dose [21, 39, 74].”
From Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities (2018) · cites this paper as [39]
In the citing paper
“and 40.7% (95% CI 34.7–46.9) of the intravenous group and 45.4% (95% CI 39.2–51.7) of the subcutaneous group achieved a pCR.”
From Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities (2018) · cites this paper as [39]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Goldhirsch, A., Wood, W. C., Coates, A. S., Gelber, R. D., Thürlimann, B., & Senn, H.-J. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr304 · Cited by 3,836
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Aebi, S., Davidson, T., Gruber, G., & Castiglione, M. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq159 · Cited by 2,842
Summary of product characteristics
(2013) · Pharmaceutical Medicine · doi:10.1093/med/9780199609147.003.0027 · Cited by 1,905
Gianni, L., Eiermann, W., Semiglazov, V., Manikhas, A., Lluch, A., Tjulandin, S., Zambetti, M., Vazquez, F., Byakhow, M., Lichinitser, M., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61964-4 · Cited by 1,255
Self-citationPegram, M., Hsu, S., Lewis, G., Pietras, R., Beryt, M., Sliwkowski, M., Coombs, D., Baly, D., Kabbinavar, F., & Slamon, D. (1999) · Oncogene · doi:10.1038/sj.onc.1202526 · Cited by 692
Cardoso, F., Fallowfield, L., Costa, A., Castiglione, M., & Senkus, E. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr372 · Cited by 596
Untch, M., Rezai, M., Loibl, S., Fasching, P. A., Huober, J., Tesch, H., Bauerfeind, I., Hilfrich, J., Eidtmann, H., Gerber, B., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.8451 · Cited by 556
Self-citationBuzdar, A. U., Valero, V., Ibrahim, N. K., Francis, D., Broglio, K. R., Theriault, R. L., Pusztai, L., Green, M. C., Singletary, S. E., Hunt, K. K., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1345 · Cited by 475
Untch, M., Loibl, S., Bischoff, J., Eidtmann, H., Kaufmann, M., Blohmer, J.-U., Hilfrich, J., Strumberg, D., Fasching, P. A., Kreienberg, R., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70397-7 · Cited by 451
Self-citationA recombinant human enzyme for enhanced interstitial transport of therapeutics
Bookbinder, L. H., Hofer, A., Haller, M. F., Zepeda, M. L., Keller, G.-A., Lim, J. E., Edgington, T. S., Shepard, H. M., Patton, J. S., & Frost, G. I. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.05.027 · Cited by 282
Research works printed but not linked: 1
- Haller, 2007, Converting intravenous dosing to subcutaneous dosing with recombinant human hyaluronidase, Pharm Tech, 10, 861
Cited by
Loibl, S., & Gianni, L. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32417-5 · Cited by 1,116
Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities
Bittner, B., Richter, W., & Schmidt, J. (2018) · BioDrugs · doi:10.1007/s40259-018-0295-0 · Cited by 447
Targeted therapeutic options and future perspectives for HER2-positive breast cancer
Wang, J., & Xu, B. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0069-2 · Cited by 393
Seo, A. N., Lee, H. J., Kim, E. J., Kim, H. J., Jang, M. H., Lee, H. E., Kim, Y. J., Kim, J. H., & Park, S. Y. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.634 · Cited by 317
“Several studies showed that the addition of trastuzumab to neoadjuvant chemotherapy significantly increased pCR rate in HER2-positive breast cancer (Buzdar et al, 2005; Gianni et al, 2010; Ismael et al, 2012).”
BackgroundSwain, S. M., Ewer, M. S., Viale, G., Delaloge, S., Ferrero, J.-M., Verrill, M., Colomer, R., Vieira, C., Werner, T. L., Douthwaite, H., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx773 · Cited by 244
Metadata
- Authors
- Ismael, G., Hegg, R., Muehlbauer, S., Heinzmann, D., Lum, B., Kim, S.-B., Pienkowski, T., Lichinitser, M., Semiglazov, V., Melichar, B., & Jackisch, C.
- Affiliations
- Hospital Amaral Carvalho (BR)
- Hospital da Mulher São Paulo (BR)
- F. Hoffmann-La Roche AG (CH)
- Genentech (US)
- Asan Medical Center (KR)
- Russian Cancer Research Center NN Blokhin (RU)
- University Hospital Olomouc (CZ)
- Sana Klinikum Offenbach (DE)
- Corresponding author
- Ismael, Gustavo
- ORCID
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2012-09
- Volume
- 13
- Issue
- 9
- Pages
- 869-878
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W2107103026
- Cited by
- 351
- References
- 22
- Citations by year
- 2026: 16 · 2025: 10 · 2024: 16 · 2023: 19 · 2022: 22 · 2021: 24 · 2020: 22 · 2019: 22 · 2018: 30 · 2017: 31 · 2016: 27 · 2015: 39 · 2014: 36 · 2013: 33 · 2012: 4
- FWCI
- 17.73
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Locations
- The Lancet Oncology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Keywords
- trastuzumab, subcutaneous administration, intravenous administration, HER2-positive breast cancer, neoadjuvant therapy, adjuvant therapy, pharmacokinetics, trough concentration, pathological complete response, docetaxel, FEC chemotherapy, non-inferiority, inflammatory breast cancer, locally advanced breast cancer, treatment safety, patient convenience, resource utilization (health care), Hannah
- MeSH terms
- Trastuzumab, Adenocarcinoma, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Cyclophosphamide, Doxorubicin, Female, Fluorouracil, Humans, Infusions, Intravenous, Middle Aged, Neoplasm Staging, Epirubicin, Disease-Free Survival, Erb-b2 Receptor Tyrosine Kinases, Receptor, ErbB-2, Neoadjuvant Therapy, Infusions, Subcutaneous, Young Adult, Neoplasm Grading, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. https://app.cochat.ai/papers/10.1016/s1470-2045(12)70329-7
- The paper
- Ismael, G., Hegg, R., Muehlbauer, S., Heinzmann, D., Lum, B., Kim, S.-B., Pienkowski, T., Lichinitser, M., Semiglazov, V., Melichar, B., & Jackisch, C. (2012). Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(12)70329-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.